| Literature DB >> 25575079 |
Marli Silva1, Laurence Daheron2, Hannah Hurley3, Kim Bure4, Richard Barker3, Andrew J Carr5, David Williams6, Hae-Won Kim7, Anna French1, Pete J Coffey8, Justin J Cooper-White9, Brock Reeve2, Mahendra Rao10, Evan Y Snyder11, Kelvin S Ng12, Benjamin E Mead12, James A Smith13, Jeffrey M Karp12, David A Brindley14, Ivan Wall15.
Abstract
Induced pluripotent stem cells (iPSCs) have the potential to transform drug discovery and healthcare in the 21(st) century. However, successful commercialization will require standardized manufacturing platforms. Here we highlight the need to define standardized practices for iPSC generation and processing and discuss current challenges to the robust manufacture of iPSC products.Mesh:
Year: 2015 PMID: 25575079 DOI: 10.1016/j.stem.2014.12.013
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633